Table 1 Characteristics of the study sample of 190 men with metastatic prostate cancer grouped on time from last questionnaire to death
Time between last questionnaire and death | < 6 months | 6–18 months | > 18 months | Total | |||||
|---|---|---|---|---|---|---|---|---|---|
Frequency (%) | 40 (21.0) | 64 (33.7) | 86 (45.3) | 190 (100.0) | |||||
Mean age (SD) | 71.5 (7.4) | 69.7 (6.3) | 71.0 (7.4) | 70.6 (7.1) | |||||
Tumour size classification, n (%) | |||||||||
(Tumour-Nodes-Metastasis system) | 20 (50) | 20 (50) | 41 (64) | 23 (36) | 53 (62) | 33 (38) | 114 (60) | 76 (40) | |
1–2 | 3–4 | ||||||||
Year of diagnosis, Median (q1-q3) | 1998 (1996–2002) | 1998 (1994–2001) | 1997 (1993–2001) | 1998 (1994–2002) | |||||
Year of death, Median (q1-q3) | 2006 (2003–2007) | 2005 (2002–2008) | 2007 (2003–2011) | 2006 (2002–2010) | |||||
Years between PC diagnosis and metastasis, Median (q1-q3) | 5 (2–8) | 4 (2.5–6) | 5.5 (3–9) | 5 (3–8) | |||||
Years between metastasis and death, Median (q1-q3) | 1 (0–2) | 2 (1–3) | 3 (1–4) | 2 (1–4) | |||||
Years with PC, from diagnosis to death, Median (q1-q3) | 6 (3–9) | 6.5 (4–10) | 9 (7–11) | 7 (5–10) | |||||
Proportion (%) receiving hormone treatments upon inclusion | 80.0 | 59.3 | 62.3 | 64.6 | |||||